Skip to main content
Erschienen in: Medical Oncology 2/2012

01.06.2012 | Original Paper

Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray

verfasst von: Jiehua He, Roujun Peng, Zhongyu Yuan, Shusen Wang, Jiewen Peng, Guinan Lin, Xiaomei Jiang, Tao Qin

Erschienen in: Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study is to analyze the prognostic value of androgen receptor (AR) expression for patients with triple-negative breast cancer (TNBC). Clinical data of these patients were collected and analyzed, and immunohistochemical staining for AR was performed on tissue microarrays of operable breast cancer from 287 patients with TNBC, who were treated at Sun Yat-sen University Cancer Center from January 1995 to December 2008. AR expression was found in 25.8% of the cases with TNBC. TNBC patients with AR negative have a higher proportion of positive lymph node. A significant correlation was found between AR expression and disease-free survival (DFS) and overall survival (OS). Univariated analysis indicated that AR expression had a significant prognostic value in TNBC patients, whereas multivariate analysis indicated that AR was a significant independent prognostic factor of DFS (P = 0.032) in all patients. Our results suggested that AR was a favorable prognostic factor of DFS and OS in patients with TNBC. Therefore, TNBC may be further divided into two subtypes according to AR status.
Literatur
1.
Zurück zum Zitat Dent R, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.PubMedCrossRef Dent R, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.PubMedCrossRef
2.
Zurück zum Zitat Carey LA, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–34.PubMedCrossRef Carey LA, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–34.PubMedCrossRef
3.
Zurück zum Zitat Tischkowitz M, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007;7:134.PubMedCrossRef Tischkowitz M, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007;7:134.PubMedCrossRef
4.
Zurück zum Zitat Bauer KR, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer. 2007;109:1721–8.PubMedCrossRef Bauer KR, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer. 2007;109:1721–8.PubMedCrossRef
5.
Zurück zum Zitat Hines SL, et al. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol. 2008;19(9):1561–5.PubMedCrossRef Hines SL, et al. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol. 2008;19(9):1561–5.PubMedCrossRef
6.
Zurück zum Zitat Lin Nu, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638–45.PubMedCrossRef Lin Nu, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638–45.PubMedCrossRef
7.
Zurück zum Zitat Nam BH, et al. Breast cancer subtypes and survival in patients with brain metastases. Br Cancer Res. 2008;10(1):R20.CrossRef Nam BH, et al. Breast cancer subtypes and survival in patients with brain metastases. Br Cancer Res. 2008;10(1):R20.CrossRef
8.
Zurück zum Zitat Schneider BP, et al. Triple negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14(24):8010–8.PubMedCrossRef Schneider BP, et al. Triple negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14(24):8010–8.PubMedCrossRef
9.
Zurück zum Zitat Brys M. Androgens and androgen receptor: do they play a role in breast cancer? Med Sci Monit. 2000;6:433–8.PubMed Brys M. Androgens and androgen receptor: do they play a role in breast cancer? Med Sci Monit. 2000;6:433–8.PubMed
10.
Zurück zum Zitat Liao DJ, et al. Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol. 2002;20:175–89.CrossRef Liao DJ, et al. Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol. 2002;20:175–89.CrossRef
11.
Zurück zum Zitat Hankinson SE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998;90:1292–9.PubMedCrossRef Hankinson SE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998;90:1292–9.PubMedCrossRef
12.
Zurück zum Zitat Doane AS, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006;25:3994–4008.PubMedCrossRef Doane AS, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006;25:3994–4008.PubMedCrossRef
13.
Zurück zum Zitat Agoff SN, et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol. 2003;120:725–31.PubMedCrossRef Agoff SN, et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol. 2003;120:725–31.PubMedCrossRef
14.
Zurück zum Zitat Gonzalez-Angulo AM, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 2009;15:2472–8.PubMedCrossRef Gonzalez-Angulo AM, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 2009;15:2472–8.PubMedCrossRef
15.
Zurück zum Zitat Kononen J, et al. Tissue microarrays for highthroughput molecular profiling of tumor specimens. Nat Med. 1998;4:844–7.PubMedCrossRef Kononen J, et al. Tissue microarrays for highthroughput molecular profiling of tumor specimens. Nat Med. 1998;4:844–7.PubMedCrossRef
Metadaten
Titel
Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray
verfasst von
Jiehua He
Roujun Peng
Zhongyu Yuan
Shusen Wang
Jiewen Peng
Guinan Lin
Xiaomei Jiang
Tao Qin
Publikationsdatum
01.06.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9832-0

Weitere Artikel der Ausgabe 2/2012

Medical Oncology 2/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.